AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16236844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 12111288 — intervention group
Group type: EXPERIMENTAL
Intervention: Weightlifters (WL)
Number of subjects: 70
Study 12111288 — intervention group
Group type: EXPERIMENTAL
Intervention: Handball players (HP)
Number of subjects: 70
Study 12111288 — intervention group
Group type: EXPERIMENTAL
Intervention: Amateur road cyclists (RC)
Number of subjects: 70
Study 12111288 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-distance runners (MDR)
Number of subjects: 70
Study 12111288 — intervention group
Group type: COMPARATOR
Intervention: Age-matched control subjects (C)
Number of subjects: 70
Study 10543650 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mL of nonionic contrast material (300 mg I/mL) at 2 mL/s
Number of subjects: 97
Study 10543650 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mL of nonionic contrast material (300 mg I/mL) at 1.5 mL/s
Number of subjects: 97
Study 10543650 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mL of nonionic contrast material (300 mg I/mL) at 3 mL/s
Number of subjects: 97
Study 10543650 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mL of nonionic contrast material (300 mg I/mL) at 4 mL/s
Number of subjects: 97
Study 7762723 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccination (first dose)
Number of subjects: 1386
Study 7762723 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccination (two doses)
Number of subjects: 1386
Study 7762723 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing vaccination program
Number of subjects: 1386
Study 1702885 — intervention group
Group type: EXPERIMENTAL
Intervention: Gordox therapy (2 M IU within 20 min after induction, followed by 0.5 M IU/hour infusion until end of operation)
Number of subjects: 37
Study 1702885 — intervention group
Group type: EXPERIMENTAL
Intervention: Gordox therapy
Number of subjects: 37
Study 1702885 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37
Study 206826 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibate and beta-pyridylcarbinol (1.000 mg clofibrate and 50 mg beta-pyridylcarbinol per day)
Number of subjects: 27
Study 206826 — intervention group
Group type: COMPARATOR
Intervention: Clofibate (1.500 mg per day)
Number of subjects: 27
Study 31916571 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial biopsy during ovarian stimulation
Number of subjects: 18
Study 31916571 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretome analysis of cultured and decidualized endometrial stromal cells (EnSCs)
Number of subjects: 18
Study 31916571 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolation and culture of EnSCs
Number of subjects: 18
Study 31380421 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Cannula (HFNC)
Number of subjects: 153
Study 31380421 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular Advancement (MA) bite block
Number of subjects: 153
Study 31380421 — intervention group
Group type: COMPARATOR
Intervention: Standard management (standard bite block and standard nasal cannula)
Number of subjects: 153
Study 27915261 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention
Number of subjects: 0
Study 27915261 — intervention group
Group type: COMPARATOR
Intervention: Control clusters
Number of subjects: 0
Study 25873303 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram plus vitamin C
Number of subjects: 43
Study 25873303 — intervention group
Group type: COMPARATOR
Intervention: Citalopram plus placebo
Number of subjects: 43
Study 24320432 — intervention group
Group type: EXPERIMENTAL
Intervention: CVT algorithm for catheter optimization
Number of subjects: 8
Study 24320432 — intervention group
Group type: EXPERIMENTAL
Intervention: CVT algorithm with implantation errors
Number of subjects: 8
Study 24320432 — intervention group
Group type: EXPERIMENTAL
Intervention: CVT algorithm parameters
Number of subjects: 8
Study 24320432 — intervention group
Group type: EXPERIMENTAL
Intervention: CVT algorithm optimization time
Number of subjects: 8
Study 24320432 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast HDR brachytherapy
Number of subjects: 8
Study 22221594 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 140
Study 22221594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 19606169 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoirrigation at 12°C
Number of subjects: 38
Study 19606169 — intervention group
Group type: COMPARATOR
Intervention: Room temperature irrigation at 25°C
Number of subjects: 38
Study 17257756 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (12 sessions over 8 weeks)
Number of subjects: 864
Study 17257756 — intervention group
Group type: COMPARATOR
Intervention: Minimal (sham) acupuncture (superficial needling of non-acupuncture points)
Number of subjects: 864
Study 15203290 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.6 g/kg)
Number of subjects: 40
Study 15203290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11445473 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic nephrectomy
Number of subjects: 20
Study 11445473 — intervention group
Group type: COMPARATOR
Intervention: Open nephrectomy
Number of subjects: 20
Study 9568752 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily
Number of subjects: 32
Study 9568752 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 40 mg daily plus cholestyramine 4 g daily
Number of subjects: 32
Study 7887103 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% wound infiltration (10 ml)
Number of subjects: 40
Study 7887103 — intervention group
Group type: COMPARATOR
Intervention: Control group (no infiltration)
Number of subjects: 40
Study 3229340 — intervention group
Group type: EXPERIMENTAL
Intervention: Zindotrine 300 mg
Number of subjects: 12
Study 3229340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29514224 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS pathway
Number of subjects: 226
Study 29514224 — intervention group
Group type: COMPARATOR
Intervention: Control (routine care)
Number of subjects: 226
Study 27450203 — intervention group
Group type: EXPERIMENTAL
Intervention: Deeper cooling (32 °C for 120 h)
Number of subjects: 0
Study 27450203 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer cooling (120 h)
Number of subjects: 0
Study 27450203 — intervention group
Group type: COMPARATOR
Intervention: Standard cooling (33.5 °C for 72 h)
Number of subjects: 0
Study 24691410 — intervention group
Group type: EXPERIMENTAL
Intervention: SWAP‐DM2
Number of subjects: 2219
Study 22918966 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5‐20 mg/day)
Number of subjects: 343
Study 22918966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343
Study 20371584 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone treatment
Number of subjects: 223
Study 20371584 — intervention group
Group type: COMPARATOR
Intervention: Non-treated patients
Number of subjects: 223
Study 18535188 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive parental history of diabetes
Number of subjects: 359
Study 18535188 — intervention group
Group type: COMPARATOR
Intervention: Negative parental history of diabetes
Number of subjects: 359
Study 18535188 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with two diabetic parents
Number of subjects: 359
Study 15920052 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney-islet group (17 patients with islet transplant)
Number of subjects: 42
Study 15920052 — intervention group
Group type: COMPARATOR
Intervention: Kidney-only group (25 patients without islet transplant)
Number of subjects: 42
Study 12217805 — intervention group
Group type: COMPARATOR
Intervention: MP alone
Number of subjects: 527
Study 12217805 — intervention group
Group type: EXPERIMENTAL
Intervention: VAD/MP
Number of subjects: 527
Study 12217805 — intervention group
Group type: EXPERIMENTAL
Intervention: VND/MP
Number of subjects: 527
Study 12217805 — intervention group
Group type: EXPERIMENTAL
Intervention: VAD/MP and VND/MP
Number of subjects: 527
Study 10600086 — intervention group
Group type: EXPERIMENTAL
Intervention: Amprenavir 1200 mg
Number of subjects: 12
Study 10600086 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 400 mg
Number of subjects: 12
Study 10600086 — intervention group
Group type: EXPERIMENTAL
Intervention: Amprenavir 1200 mg plus Ketoconazole 400 mg
Number of subjects: 12
Study 8743497 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein diet (0.58 g/kg body wt/day)
Number of subjects: 840
Study 8743497 — intervention group
Group type: EXPERIMENTAL
Intervention: Low blood pressure goal (92 mm Hg)
Number of subjects: 840
Study 8743497 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low protein diet (0.28 g/kg body wt/day supplemented with keto acids and amino acids)
Number of subjects: 840
Study 8743497 — intervention group
Group type: COMPARATOR
Intervention: Usual protein diet (1.3 g/kg body wt/day)
Number of subjects: 840
Study 8743497 — intervention group
Group type: COMPARATOR
Intervention: Usual blood pressure (107 mm Hg)
Number of subjects: 840
Study 1817915 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic root cleansing with 0.1% chlorhexidine gluconate as a coolant
Number of subjects: 10
Study 1817915 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic root cleansing without chlorhexidine gluconate
Number of subjects: 10
Study 7046604 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Anaesthesia (LA)
Number of subjects: 103
Study 7046604 — intervention group
Group type: COMPARATOR
Intervention: General Anaesthesia (GA)
Number of subjects: 103
Study 31806073 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resource setting
Number of subjects: 10
Study 31806073 — intervention group
Group type: COMPARATOR
Intervention: Low-resource setting
Number of subjects: 10
Study 30894658 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting-up position (head elevated ≥30°)
Number of subjects: 9156
Study 30894658 — intervention group
Group type: COMPARATOR
Intervention: Lying-flat position (0°)
Number of subjects: 9156
Study 30894658 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall association of CV of systolic BP (SBP)
Number of subjects: 9156
Study 28835586 — intervention group
Group type: EXPERIMENTAL
Intervention: ≤15 mg/day additive tolvaptan (TLV)
Number of subjects: 81
Study 28835586 — intervention group
Group type: COMPARATOR
Intervention: ≤40 mg/day increased furosemide (FUR)
Number of subjects: 81
Study 26911639 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 1,600 mg once daily
Number of subjects: 2
Study 26911639 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 1,200 mg once daily
Number of subjects: 2
Study 24362944 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir (TVR) plus PEG‐IFN and ribavirin therapy
Number of subjects: 87
Study 24362944 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir (TVR) plus PEG‐IFN and ribavirin therapy with IFNL4 TT/TT genotype
Number of subjects: 87
Study 24362944 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir (TVR) plus PEG‐IFN and ribavirin therapy with IFNL4 TT/ΔG or ΔG/ΔG genotypes
Number of subjects: 87
Study 24362944 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir (TVR) at a reduced dose of 1,500 mg per day
Number of subjects: 87
Study 24362944 — intervention group
Group type: COMPARATOR
Intervention: Younger patients (≤65 years) receiving the same therapy
Number of subjects: 87
Study 22371012 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent reports
Number of subjects: 270
Study 22371012 — intervention group
Group type: COMPARATOR
Intervention: Teacher reports
Number of subjects: 270
Study 19386059 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week walking program
Number of subjects: 128
Study 19386059 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance stage walking
Number of subjects: 128
Study 19386059 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower education level
Number of subjects: 128
Study 17570908 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine at peak level
Number of subjects: 40
Study 17570908 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone at peak level
Number of subjects: 40
Study 17570908 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone at trough level
Number of subjects: 40
Study 17570908 — intervention group
Group type: EXPERIMENTAL
Intervention: Trough level (both substances)
Number of subjects: 40
Study 17570908 — intervention group
Group type: COMPARATOR
Intervention: Medication-free control group
Number of subjects: 40
Study 15468027 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiwavelength light therapy (14 sessions, 3 times a week, energy used was 4.5 J/cm(2))
Number of subjects: 35
Study 15468027 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (control group)
Number of subjects: 35
Study 15468027 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiwavelength light therapy (for stage 3 and 4 ulcers)
Number of subjects: 35
Study 15468027 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (control group for stage 3 and 4 ulcers)
Number of subjects: 35
Study 11696741 — intervention group
Group type: COMPARATOR
Intervention: 5 mg. oxybutynin orally
Number of subjects: 12
Study 11696741 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive diffusion of 5 mg. oxybutynin intravesically
Number of subjects: 12
Study 11696741 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromotive administration of 15 mg. oxybutynin
Number of subjects: 12
Study 9710387 — intervention group
Group type: EXPERIMENTAL
Intervention: Music during surgery
Number of subjects: 78
Study 9710387 — intervention group
Group type: COMPARATOR
Intervention: No music
Number of subjects: 78
Study 9710387 — intervention group
Group type: COMPARATOR
Intervention: Music and No music
Number of subjects: 78
Study 8027416 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (up to 7 mg/kg per day) and Carbidopa (100 mg/day)
Number of subjects: 50
Study 8027416 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules (four times a day)
Number of subjects: 50
Study 2678794 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimobendan
Number of subjects: 40
Study 2678794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 4348345 — intervention group
Group type: EXPERIMENTAL
Intervention: p-hydroxynorephedrine (PHN) 600 mg daily
Number of subjects: 8
Study 4348345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 28840328 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mm instruments
Number of subjects: 24
Study 28840328 — intervention group
Group type: COMPARATOR
Intervention: 5 mm instruments
Number of subjects: 24
Study 27633880 — intervention group
Group type: EXPERIMENTAL
Intervention: CRS + HIPEC with lobaplatin 50 mg/m² and docetaxel 60 mg/m² in 6000 mL of normal saline at 43 ± 0.5 °C for 60 min
Number of subjects: 100
Study 27633880 — intervention group
Group type: EXPERIMENTAL
Intervention: CRS + HIPEC with lobaplatin and docetaxel
Number of subjects: 100
Study 24725787 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting Active Lag Test
Number of subjects: 56
Study 24725787 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone Passive Lag Test
Number of subjects: 56
Study 22536989 — intervention group
Group type: EXPERIMENTAL
Intervention: PST delivered face-to-face (Group 1)
Number of subjects: 126
Study 22536989 — intervention group
Group type: COMPARATOR
Intervention: PST delivered via videophone (Group 2)
Number of subjects: 126
Study 20118346 — intervention group
Group type: EXPERIMENTAL
Intervention: Polidocanol foam sclerotherapy
Number of subjects: 100
Study 20118346 — intervention group
Group type: COMPARATOR
Intervention: Polidocanol liquid sclerotherapy
Number of subjects: 100
Study 18209013 — intervention group
Group type: EXPERIMENTAL
Intervention: FLIRI (irinotecan 180 mg/m(2) on day 1, 5‐FU 500 mg/m(2) and FA 60 mg/m(2) on day 1 and 2)
Number of subjects: 567
Study 18209013 — intervention group
Group type: COMPARATOR
Intervention: Lv5FU2-IRI (irinotecan 180 mg/m(2) on day 1, FA 200 mg/m(2), 5‐FU bolus 400 mg/m(2) and infused 5‐FU 600 mg/m(2) on day 1 and 2)
Number of subjects: 567
Study 18209013 — intervention group
Group type: EXPERIMENTAL
Intervention: FLIRI
Number of subjects: 567
Study 18209013 — intervention group
Group type: COMPARATOR
Intervention: Lv5FU2-IRI
Number of subjects: 567
Study 15180233 — intervention group
Group type: EXPERIMENTAL
Intervention: Early individualized postoperative occupational therapy (OT) program
Number of subjects: 100
Study 15180233 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (Control)
Number of subjects: 100
Study 11281614 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (2 x 500 mg tablets daily)
Number of subjects: 16
Study 11281614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9885441 — intervention group
Group type: EXPERIMENTAL
Intervention: Response-oriented induction therapy consisting of doxorubicin, vincristine, cyclophosphamide, L-asparaginase, and prednisolone.
Number of subjects: 116
Study 9885441 — intervention group
Group type: EXPERIMENTAL
Intervention: Response-oriented induction therapy with intrathecal chemotherapy on day 8.
Number of subjects: 116
Study 9885441 — intervention group
Group type: COMPARATOR
Intervention: Response-oriented induction therapy without intrathecal chemotherapy on day 8.
Number of subjects: 116
Study 9885441 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival and event-free survival (EFS) rates at 6 years.
Number of subjects: 116
Study 9885441 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete remission (CR) patients' survival rates.
Number of subjects: 116
Study 9885441 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and platelet count as prognostic factors.
Number of subjects: 116
Study 9885441 — intervention group
Group type: EXPERIMENTAL
Intervention: Days to complete remission (CR) and age as favorable factors for DFS.
Number of subjects: 116
Study 7994784 — intervention group
Group type: EXPERIMENTAL
Intervention: TUR + intravesical epirubicin (20 mg/40 ml, 30 times/2 years)
Number of subjects: 129
Study 7994784 — intervention group
Group type: COMPARATOR
Intervention: TUR-alone group
Number of subjects: 129
Study 2688083 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin
Number of subjects: 132
Study 2688083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 31735542 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight stigma news article (N=75)
Number of subjects: 172
Study 31735542 — intervention group
Group type: COMPARATOR
Intervention: Smoking stigma news article (N=97)
Number of subjects: 172
Study 27604070 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K supplementation
Number of subjects: 401
Study 27604070 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin K supplementation)
Number of subjects: 401
Study 25597266 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment (ART)
Number of subjects: 99
Study 25597266 — intervention group
Group type: COMPARATOR
Intervention: Conventional restorative technique (CT)
Number of subjects: 99
Study 23867958 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surfactant use for respiratory distress syndrome, perinatal aspiration syndrome, and pneumonia/sepsis
Number of subjects: 299
Study 23867958 — intervention group
Group type: EXPERIMENTAL
Intervention: Early inhaled nitric oxide (iNO)
Number of subjects: 299
Study 23867958 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygenation index (OI) <20 at enrollment
Number of subjects: 299
Study 23867958 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant use before randomization
Number of subjects: 299
Study 21224020 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine 10mg
Number of subjects: 0
Study 21224020 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study 19241171 — intervention group
Group type: EXPERIMENTAL
Intervention: STI/HIV risk reduction group
Number of subjects: 522
Study 19241171 — intervention group
Group type: COMPARATOR
Intervention: General health promotion group
Number of subjects: 522
Study 16373993 — intervention group
Group type: COMPARATOR
Intervention: 0 g of alpha-cyclodextrin (control)
Number of subjects: 10
Study 16373993 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of alpha-cyclodextrin
Number of subjects: 10
Study 16373993 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g of alpha-cyclodextrin
Number of subjects: 10
Study 16373993 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g of alpha-cyclodextrin
Number of subjects: 10
Study 16373993 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-cyclodextrin (all doses)
Number of subjects: 10
Study 16373993 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of alpha-cyclodextrin
Number of subjects: 10
Study 15037882 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard behavioral treatment with exercise level of 4186 kJ/week (1000 kcal/week)
Number of subjects: 202
Study 15037882 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard behavioral treatment with exercise level of 10465 kJ/week (2500 kcal/week)
Number of subjects: 202
Study 10910003 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment (0.04 IU/kg) for 4 weeks
Number of subjects: 18
Study 10910003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 9533345 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Amlexanox oral paste (Aphthasol)
Number of subjects: 1124
Study 9533345 — intervention group
Group type: COMPARATOR
Intervention: Vehicle treatment
Number of subjects: 1124
Study 9533345 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 1124
Study 8276984 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen, 50 mg b.d. for 21 days
Number of subjects: 21
Study 8276984 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen, 50 mg b.d. for 7 days (post-treatment)
Number of subjects: 21
Study 8276984 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control group Cl, n = 14)
Number of subjects: 21
Study 2882767 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. temazepam (both injectable forms: 90% propylene glycol and 40% salicylic acid)
Number of subjects: 0